The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study
Abstract
Introduction: Autoimmunity against the TSH receptor is a key pathogenic element in Graves' disease. The autoimmune aberration may be modified by therapy of the hyperthyroidism. Objective: To compare the effects of the common types of therapy for Graves' hyperthyroidism on TSH-receptor autoimmunity. Methods: Patients with newly diagnosed Graves' hyperthyroidism aged 20–55 years were randomized to medical therapy, thyroid surgery, or radioiodine therapy (radioiodine was only given to patients ≥35 years of age). l -thyroxine ( l -T 4 ) was added to therapy as appropriate to keep patients euthyroid. Anti-thyroid drugs were withdrawn after 18 months of therapy. TSH-receptor antibodies (TRAb) in serum were measured before and for 5 years after the initiation of therapy. Results: Medical therapy ( n =48) and surgery ( n =47) were followed by a gradual decrease in TRAb in serum, with the disappearance of TRAb in 70–80% of the patients after 18 months. Radioiodine therapy ( n =36) led to a 1-year long worsening of autoimmunity against the TSH receptor, and the number of patients entering remission of TSH-receptor autoimmunity with the disappearance of TRAb from serum during the following years was considerably lower than with the other types of therapy. Conclusion: The majority of patients with Graves' disease gradually enter remission of TSH-receptor autoimmunity during medical or after surgical therapy, with no difference between the types of therapy. Remission of TSH-receptor autoimmunity after radioiodine therapy is less common.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the group with elevated TRAb, relapse rates approach 80%-100%, while in the latter group, relapse rates are in the 20%-30% range (171,172).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [172]
In the citing paper
“TRAb assessment at the end of the course of ATD therapy is a useful method of dividing patients into two groups: one with persistent elevations who are unlikely to be in remission, and another group with low or undetectable TRAb, who have a higher probability of permanent remission (171,172).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [172]
In the citing paper
“Whereas monitoring of TRAb levels while on ATDs has been shown to be useful in adult patients for predicting the likelihood of remission or relapse of GD after stopping the medication (172), this approach has yet to be validated in children.”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [172]
In the citing paper
“The higher risk of GO development after RAI therapy in the majority of studies may be related to the unique increase in TRAb levels observed following this therapy (172).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [172]
Citations
Cites
Relation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy
Bartalena, L., Marcocci, C., Bogazzi, F., Manetti, L., Tanda, M. L., Dell'Unto, E., Bruno-Bossio, G., Nardi, M., Bartolomei, M. P., Lepri, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380201 · Cited by 715
Occurrence of Ophthalmopathy after Treatment for Graves' Hyperthyroidism
Tallstedt, L., Lundell, G., Tørring, O., Wallin, G., Ljunggren, J.-G., Blomgren, H., & Taube, A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206253262603 · Cited by 521
Self-citationEpidemiology and Prevention of Graves' Ophthalmopathy
Wiersinga, W. M., & Bartalena, L. (2002) · Thyroid · doi:10.1089/105072502761016476 · Cited by 457
Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy
Gerding, M. N., Meer, J. W. C. V. D., Broenink, M., Bakker, O., Wiersinga, W. M., & Prummel, M. F. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.00959.x · Cited by 328
Törring, O., Tallstedt, L., Wallin, G., Lundell, G. E. F., Ljunggren, J. ‐., Taube, A., Sääf, M., & Hamberger, B. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.8.8768863 · Cited by 311
Self-citationCarbimazole and the Autoimmune Response in Graves' Disease
McGregor, A. M., Petersen, M. M., McLachlan, S. M., Rooke, P., Smith, B. R., & Hall, R. (1980) · New England Journal of Medicine · doi:10.1056/nejm198008073030603 · Cited by 274
Thyrotropin receptor-associated diseases: from adenomata to Graves disease
Davies, T. F. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26031 · Cited by 260
Fatourechi, V. (2005) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200506050-00003 · Cited by 207
LIPPE, B. M., LANDAW, E. M., & KAPLAN, S. A. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-6-1241 · Cited by 192
Laurberg, P., Nygaard, B., Glinoer, D., Grussendorf, M., & Orgiazzi, J. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1390584 · Cited by 191
Self-citation
Research works printed but not linked: 8
- 1992, New England Journal of Medicine, 25, 1733
- Torring, 1996, Journal of Clinical Endocrinology & Metabolism, 81, 2986, 10.1210/jc.81.8.2986 · DOI
- Smith, 2004, Thyroid : official journal of the American Thyroid Association, 14, 830, 10.1089/1050725042451248 · DOI
- 1980, New England Journal of Medicine, 7, 302
- Kung, 1994, Journal of Clinical Endocrinology & Metabolism, 79, 542, 10.1210/jc.79.2.542 · DOI
- 1998, New England Journal of Medicine, 8, 73
- 1979, JAMA, 30, 2408
- 2005, New England Journal of Medicine, 3, 905
Cited by
Sorted by citations
Stagnaro-Green, A., Abalovich, M., Alexander, E., Azizi, F., Mestman, J., Negro, R., Nixon, A., Pearce, E. N., Soldin, O. P., Sullivan, S., et al. (2011) · Thyroid · doi:10.1089/thy.2011.0087 · Cited by 2,942
Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., et al. (2016) · Thyroid® · doi:10.1089/thy.2016.0229 · Cited by 2,938
“In the majority of patients with GD, ATD therapy is followed by a gradual remission of disease with a possibility of disappearance of TRAb from circulation (172).”
BackgroundMethodInfluentialSelf-citationAlexander, E. K., Pearce, E. N., Brent, G. A., Brown, R. S., Chen, H., Dosiou, C., Grobman, W. A., Laurberg, P., Lazarus, J. H., Mandel, S. J., et al. (2017) · Thyroid® · doi:10.1089/thy.2016.0457 · Cited by 2,731
Self-citationBartalena, L., Kahaly, G. J., Baldeschi, L., Dayan, C. M., Eckstein, A. K., Marcocci, C., Marinò, M., Vaidya, B., Wiersinga, W. M., _, _., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0479 · Cited by 1,166
Bahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., Rivkees, S. A., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.3.456 · Cited by 1,098
Self-citation
Metadata
- Authors
- Laurberg, P., Wallin, G., Tallstedt, L., Abraham-Nordling, M., Lundell, G., & Tørring, O.
- Affiliations
- Aalborg University Hospital (DK)
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
- Corresponding author
- Laurberg, Peter
- ORCID
- Wallin, Göran
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-01
- Volume
- 158
- Issue
- 1
- Pages
- 69-75
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2161176285
- Cited by
- 428
- References
- 36
- Citations by year
- 2026: 7 · 2025: 32 · 2024: 22 · 2023: 19 · 2022: 30 · 2021: 31 · 2020: 30 · 2019: 28 · 2018: 30 · 2017: 19 · 2016: 19 · 2015: 29 · 2014: 28 · 2013: 21 · 2012: 27
- FWCI
- 8.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Eye Disorders
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- Graves' disease, TSH receptor antibodies, antithyroid drugs, thyroid surgery, radioiodine therapy, hyperthyroidism treatment, levothyroxine
- MeSH terms
- Adult, Autoantibodies, Graves Disease, Humans, Iodine Radioisotopes, Middle Aged, Prospective Studies, Receptors, Thyrotropin, Antithyroid Agents, Thyroidectomy, Thyroxine, Time Factors, Triiodothyronine, Autoimmunity, Treatment Outcome, Immunoglobulins, Thyroid-Stimulating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
